A pivotal, Phase III trial of WT1 peptide vaccine in patients with Malignant Pleural Mesothelioma.

Trial Profile

A pivotal, Phase III trial of WT1 peptide vaccine in patients with Malignant Pleural Mesothelioma.

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Galinpepimut S (Primary)
  • Indications Mesothelioma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2016 Planned initiation date changed from 1 Apr 2016 to 31 Dec 2017,as reported by SELLA Life Science media release.
    • 19 Sep 2016 SELLAS plans to commence this trial in the second half of 2017, as reported by media release.
    • 30 Nov 2015 Planned initiation date changed from 1 Jan 2016 to 1 Apr 2016, as reported by SELLA Life Science media release..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top